Sjogren's Syndrome Clinical Trials, Pipeline Analysis, EMA, PDMA, FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight

(Albany, United States) As per DelveInsight's assessment, globally, Sjogren's Syndrome pipeline constitutes 20+ key companies continuously working towards developing 22+ Sjogren's Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Sjogren's Syndrome Pipeline Insight" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sjogren's Syndrome Market.

The Sjogren's Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample report @ https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Sjogren's Syndrome Pipeline Report:
• Sjogren's Syndrome Companies across the globe are diligently working toward developing novel Sjogren's Syndrome treatment therapies with a considerable amount of success over the years.
• Sjogren's Syndrome companies working in the treatment market are Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and others, are developing therapies for the Sjogren's Syndrome treatment
• Emerging Sjogren's Syndrome therapies in the different phases of clinical trials are- R-2487, BMS-986325, RSLV-132, CFZ533, VIB4920, VAY736, Dazodalibep (VIB4920), OXERVATE (cenegermin), Tivanisiran (SYL1001), Lusvertikimab (formerly OSE-127), Nipocalimab, and others are expected to have a significant impact on the Sjogren's Syndrome market in the coming years.
• In November 2024, Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to nipocalimab for treating adults with moderate-to-severe Sjögren's disease (SjD), a chronic autoantibody condition with significant prevalence and no approved advanced treatments available. Nipocalimab is the first investigational therapy to receive this designation for SjD. This marks the second BTD granted for nipocalimab, following the February designation for treating alloimmunized pregnant individuals at high risk of severe hemolytic disease of the fetus and newborn (HDFN).
• In June 2024, Johnson & Johnson reported results from the Phase II DAHLIAS dose-ranging study, where its monoclonal antibody nipocalimab showed significant improvements in Sjögren's disease (SjD) activity in patients. DAHLIAS is a randomized, multicenter, placebo-controlled, double-blind trial that assessed the effects of nipocalimab in adults with primary SjD, a chronic and debilitating autoimmune disorder.

Sjogren's Syndrome Overview
Sjögren's syndrome is a chronic autoimmune disorder that primarily affects the glands that produce saliva and tears. In this syndrome, the immune system mistakenly attacks and damages the glands, leading to a reduction in the production of saliva and tears. While it most commonly affects the salivary and lacrimal (tear) glands, it can also impact other organs and systems in the body.

Get a Free Sample PDF Report to know more about Sjogren's Syndrome Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Sjogren's Syndrome Drugs Under Different Phases of Clinical Development Include:
• R-2487: Rise Therapeutics
• BMS-986325: Bristol-Myers Squibb
• RSLV-132: Resolve Therapeutics
• CFZ533: Novartis
• VIB4920: Horizon Therapeutics
• VAY736: Novartis
• Dazodalibep (VIB4920): Horizon Therapeutics (Amgen)
• OXERVATE (cenegermin): Dompe Farmaceutici
• Tivanisiran (SYL1001): Sylentis
• Lusvertikimab (formerly OSE-127): OSE Immunotherapeutics/Servier
• Nipocalimab: Johnson & Johnson

Sjogren's Syndrome Route of Administration
Sjogren's Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Sjogren's Syndrome Molecule Type
Sjogren's Syndrome Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Sjogren's Syndrome Pipeline Therapeutics Assessment
• Sjogren's Syndrome Assessment by Product Type
• Sjogren's Syndrome By Stage and Product Type
• Sjogren's Syndrome Assessment by Route of Administration
• Sjogren's Syndrome By Stage and Route of Administration
• Sjogren's Syndrome Assessment by Molecule Type
• Sjogren's Syndrome by Stage and Molecule Type

DelveInsight's Sjogren's Syndrome Report covers around 22+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Sjogren's Syndrome product details are provided in the report. Download the Sjogren's Syndrome pipeline report to learn more about the emerging Sjogren's Syndrome therapies
https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Sjogren's Syndrome Therapeutics Market include:
Key companies developing therapies for Sjogren's Syndrome are - Novartis, Johnson & Johnson, Dompe Farmaceutici, Sylentis, MorphoSys, Resolve Therapeutics, OSE Immunotherapeutics, Horizon Therapeutics (Amgen), Servier, and others.

Sjogren's Syndrome Pipeline Analysis:
The Sjogren's Syndrome pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Sjogren's Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sjogren's Syndrome Treatment.
• Sjogren's Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sjogren's Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sjogren's Syndrome market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Sjogren's Syndrome drugs and therapies
https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sjogren's Syndrome Pipeline Market Drivers
• Increasing Prevalence, development of better Classification Criteria, increased research and development are some of the important factors that are fueling the Sjogren's Syndrome Market.

Sjogren's Syndrome Pipeline Market Barriers
• However, lack of specific therapeutic approaches, limited translation of Therapies into the real world and other factors are creating obstacles in the Sjogren's Syndrome Market growth.

Scope of Sjogren's Syndrome Pipeline Drug Insight
• Coverage: Global
• Key Sjogren's Syndrome Companies: Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and others
• Key Sjogren's Syndrome Therapies: R-2487, BMS-986325, RSLV-132, CFZ533, VIB4920, VAY736, Dazodalibep (VIB4920), OXERVATE (cenegermin), Tivanisiran (SYL1001), Lusvertikimab (formerly OSE-127), Nipocalimab, and others
• Sjogren's Syndrome Therapeutic Assessment: Sjogren's Syndrome current marketed and Sjogren's Syndrome emerging therapies
• Sjogren's Syndrome Market Dynamics: Sjogren's Syndrome market drivers and Sjogren's Syndrome market barriers

Request for Sample PDF Report for Sjogren's Syndrome Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Sjogren's Syndrome Report Introduction
2. Sjogren's Syndrome Executive Summary
3. Sjogren's Syndrome Overview
4. Sjogren's Syndrome- Analytical Perspective In-depth Commercial Assessment
5. Sjogren's Syndrome Pipeline Therapeutics
6. Sjogren's Syndrome Late Stage Products (Phase II/III)
7. Sjogren's Syndrome Mid Stage Products (Phase II)
8. Sjogren's Syndrome Early Stage Products (Phase I)
9. Sjogren's Syndrome Preclinical Stage Products
10. Sjogren's Syndrome Therapeutics Assessment
11. Sjogren's Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Sjogren's Syndrome Key Companies
14. Sjogren's Syndrome Key Products
15. Sjogren's Syndrome Unmet Needs
16 . Sjogren's Syndrome Market Drivers and Barriers
17. Sjogren's Syndrome Future Perspectives and Conclusion
18. Sjogren's Syndrome Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Adrenal Cortex Neoplasms Market: https://www.delveinsight.com/report-store/adrenocortical-carcinoma-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Pharma Licensing Services: https://www.delveinsight.com/consulting/licensing-services
• Allergic Rhinitis Market: https://www.delveinsight.com/report-store/allergic-rhinitis-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Burkitt Lymphoma Market: https://www.delveinsight.com/report-store/burkitt-lymphoma-market
• Chronic Rhinosinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-market
• Chronic Rhinosinustis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-market
• Contraceptive Devices Market: https://www.delveinsight.com/report-store/contraceptive-devices-market
• Febrile Neutropenia Market: https://www.delveinsight.com/report-store/febrile-neutropenia-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Non-st Segment Elevation Acute Coronary Syndromes Market: https://www.delveinsight.com/report-store/non-st-segment-elevation-acute-coronary-syndromes-nste-acss-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Walking Impairment In Multiple Sclerosis Market: https://www.delveinsight.com/report-store/walking-impairment-in-multiple-sclerosis-market
• Acute On Liver Failure Market: https://www.delveinsight.com/report-store/acute-liver-failure-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Anal Cancer Market: https://www.delveinsight.com/report-store/anal-cancer-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/
Case Study: https://www.delveinsight.com/case-study/conference-intelligence-product-assessment

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.